Glaukos Corporation recently unveiled its Investor Presentation, focusing on its core growth strategy involving leading-edge innovation aimed at addressing clinical needs within large or underserved patient populations. The company is committed to challenging conventional paradigms to enhance care standards and outcomes through dropless therapies and commercial excellence. Glaukos highlights its innovation-driven approach with five novel platforms, including iStent, iDose, iLink, iLution, and Retina XR, targeting four therapeutic areas: Glaucoma, Rare Disease, Anterior Segment, and Posterior Segment. The presentation also emphasizes significant investment in research and development since 2018, with disclosed pipeline programs in 2025 increasing significantly from 2015. Key commercial catalysts for 2025-26 focus on foundational therapies that elevate care standards. You can access the full presentation through the link below.